Skip to main content

REVIEW article

Front. Surg.
Sec. Genitourinary Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1429831

Advances in Multiparametric Magnetic Resonance Imaging Combined with Biomarkers for the Diagnosis of High-grade Prostate Cancer

Provisionally accepted
Songlin Li Songlin Li 1Mingyong Zha Mingyong Zha 1Qi Wang Qi Wang 2*Yong Tang Yong Tang 1*
  • 1 Urology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi Zhuang Region, China
  • 2 Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Region, China

The final, formatted version of the article will be published soon.

    Clinical decisions based on the test results for prostate-specific antigen often result in overdiagnosis and overtreatment. Multiparametric magnetic resonance imaging (mpMRI) can be used to identify high-grade prostate cancer (HGPCa; Gleason score ≥ 3+4); however, certain limitations remain such as inter-reader variability and false negatives. The combination of mpMRI and prostate cancer (PCa) biomarkers (prostatespecific antigen density, TMPRSS2:ERG gene fusion, Michigan Prostate Score, ExoDX Prostate Intelliscore, Kallikrein 4Kscore, Select Molecular Diagnosis, Prostate Health Index, and Prostate Health Index density) demonstrates high accuracy in the diagnosis of HGPCa, ensuring that patients avoid unnecessary prostate biopsies with a low leakage rate. This manuscript describes the characteristics and diagnostic performance of each biomarker alone and in combination with mpMRI, with the intension to provide a basis for decision-making in the diagnosis and treatment of HGPCa. Additionally, we explored the applicability of the combination protocol to the Asian population.

    Keywords: High-grade prostate cancer, Multiparametric magnetic resonance imaging, biomarker, Pre-diagnosis, asian

    Received: 08 May 2024; Accepted: 27 Jun 2024.

    Copyright: © 2024 Li, Zha, Wang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Qi Wang, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi Zhuang Region, China
    Yong Tang, Urology, Wuming Hospital Affiliated to Guangxi Medical University, Nanning, Guangxi Zhuang Region, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.